CoronavirusCovid-19Health

Safety Board Wary of AstraZeneca’s COVID Vaccine Trial Data

An independent review board has cast doubt on the findings for AstraZeneca’s coronavirus vaccine candidate, saying the drugmaker’s efficacy claims may have been based on outdated data.

AstraZeneca on Monday reported that its coronavirus vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization, citing U.S. clinical trial data.

But the National Institute of Allergy and Infectious Diseases said in a statement Tuesday that the Data and Safety Monitoring Board (DSMB) voiced its concerns about the initial data from AstraZeneca’s vaccine clinical trial, saying that the company may have included outdated information from that trial, which may have provided an incomplete view, CNN reported.

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible,” the institute said in the statement, CNN reported.

The safety board operates as an autonomous expert group of 10-15 members who specialize in vaccine development, statistics and ethics, that examines all trial data before the pharmaceutical companies, doctors managing the trials and the Food and Drug Administration. The DSMB has the power to advise a company of positive findings or halt trials for safety concerns, CNN reported.

The board also reviewed vaccine candidates from Moderna and Johnson & Johnson, both of which were ultimately granted emergency authorization by the FDA, CNN reported.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker